Key result
Finerenone cuts composite cardiovascular events ~14% vs. placebo, regardless of baseline ASCVD history.
Why the study?
Finerenone improves CV and kidney outcomes in T2D and CKD, but its efficacy and safety compared with placebo in patients with versus without a baseline history of ASCVD warranted evaluation.
Does finerenone reduce cardiovascular and kidney outcomes in patients with T2D and CKD, irrespective of baseline ASCVD?
RCT (n=13,026)
Double-blind
1:1
Yes
Does finerenone reduce cardiovascular and kidney outcomes in patients with T2D and CKD, irrespective of baseline ASCVD?
Hazard Ratio: 0.86 (95% CI 0.78–0.95)
p-value: p=0.0018
Finerenone provides consistent cardiovascular and kidney benefits in patients with T2D and CKD, irrespective of baseline ASCVD status.
No takes yet. Share an insight, caveat, or question.
Supports finerenone across ASCVD strata in T2D-CKD; confirms consistent CV benefit in pooled RCT data.
Filippatos et al. (2022) conducted an RCT in Type 2 diabetes and chronic kidney disease (n=13,026). Finerenone vs. Placebo was evaluated on Composite cardiovascular outcome (time to first event of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) (HR 0.86, 95% CI 0.78-0.95, p=0.0018). Finerenone significantly reduced the risk of the primary composite cardiovascular outcome compared with placebo (HR 0.86), with consistent benefits observed regardless of baseline atherosclerotic cardiovascular disease history.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: